Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

Saved in:
Bibliographic Details
Published inBritish Journal of Haematology Vol. 182; no. 4; pp. 583 - 586
Main Authors Dang, Nam H., Ogura, Michinori, Castaigne, Sylvie, Fayad, Luis E., Jerkeman, Mats, Radford, John, Pezzutto, Antonio, Bondarenko, Igor, Stewart, Douglas A., Shnaidman, Michael, Sullivan, Sharon, Vandendries, Erik, Tobinai, Kensei, Ramchandren, Radhakrishnan, Hamlin, Paul A., Giné, Eva, Ando, Kiyoshi
Format Journal Article
LanguageEnglish
Published England Wiley 01.08.2018
Blackwell Publishing Ltd
Subjects
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibody-drug conjugate
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
B-cell non-Hodgkin lymphoma
Cancer and Oncology
Cancer och onkologi
CD22
Chemotherapy
Clinical Medicine
Female
Hematology
Humans
Immunotherapy
Inotuzumab ozogamicin
Klinisk medicin
Letter
Lymphocytes B
Lymphoma
Lymphoma, B-Cell - drug therapy
Lymphoma, B-Cell - mortality
Lymphoma, B-Cell - pathology
Male
Medical and Health Sciences
Medicin och hälsovetenskap
Middle Aged
Monoclonal antibodies
Non-Hodgkin's lymphoma
ResearchInstitutes_Networks_Beacons/mcrc; name=Manchester Cancer Research Centre
Rituximab
Rituximab - administration & dosage
Rituximab - adverse effects
Targeted cancer therapy
B-cell non-Hodgkin lymphoma
antibody-drug conjugate
inotuzumab ozogamicin
CD22
rituximab
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Correspondence-3
content type line 23
ObjectType-Undefined-4
NHD, MO, SC, LEF, MJ, JR, AP, IB, DAS, KT, RR, PAH, EG and KA participated in the collection, interpretation and analysis of data and the development of the manuscript draft. MS, SS and EV participated in study design, the interpretation and analysis of data and the development of the manuscript
Author contributions
ISSN:0007-1048
1365-2141
1365-2141
DOI:10.1111/bjh.14820